Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05014087 · ClinicalTrials.gov registry record · Phase 2
Digoxin In Treatment of Alcohol Associated Hepatitis
A Phase 2 study, sponsored by Yale University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT05014087 is a Phase 2 study that was terminated before completion, run by Yale University. The registered enrollment target is 23 participants.
The verdict
NCT05014087, a Phase 2 study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
Prospective, single center, open label, randomized controlled trial to explore whether digoxin treatment affects cytokine levels as biomarkers of inflammation in patients with acute alcohol associated hepatitis, digoxin administration and dose adjustment. The study intervention will be intravenous digoxin (renal-based dosing for maximum of 28 days) versus no digoxin in an open-label 1:1 randomized allocation of patients with severe acute alcohol associated hepatitis.
Interventions
- DRUG Intravenous digoxin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2021-10-08 |
| Est. Completion | 2025-09-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05014087
The ClinicalTrials.gov registry entry for NCT05014087 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Intravenous digoxin is the first listed.
NCT05014087 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05014087 about?
NCT05014087 is a clinical study titled "Digoxin In Treatment of Alcohol Associated Hepatitis". Prospective, single center, open label, randomized controlled trial to explore whether digoxin treatment affects cytokine levels as biomarkers of inflammation in patients with acute alcohol associated hepatitis, digoxin administration and dose adjustment. The study intervention will be intravenous ...
What is the current status of trial NCT05014087?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2021-10-08. Estimated completion is 2025-09-12.
What interventions are being tested in trial NCT05014087?
The interventions under investigation include: Intravenous digoxin (DRUG).
Who is sponsoring clinical trial NCT05014087?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.